{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:55:26Z","timestamp":1791060926104,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","award":["IIS-ML42922"],"award-info":[{"award-number":["IIS-ML42922"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Vessels, Thrombosis & Hemostasis"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bvth.2026.100200","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T16:29:02Z","timestamp":1786638542000},"page":"100200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Emicizumab enables rapid tolerance, reducing bleeding during low-dose ITI in pediatric hemophilia A"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1191-1654","authenticated-orcid":false,"given":"Carolina","family":"Costa-Lima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3003-3775","authenticated-orcid":false,"given":"Vanessa B.","family":"Faiotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9679-2986","authenticated-orcid":false,"given":"Ana P.","family":"Francisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9455-7640","authenticated-orcid":false,"given":"N\u00edvia M.","family":"Foschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5224-5358","authenticated-orcid":false,"given":"Samuel S.","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5942-1083","authenticated-orcid":false,"given":"Marina P.","family":"Colella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8920-3765","authenticated-orcid":false,"given":"Silmara A.","family":"Lima Montalv\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0350-8171","authenticated-orcid":false,"given":"Gabriela G.","family":"Yamaguti-Hayakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1008-4458","authenticated-orcid":false,"given":"J\u00e9ssica O.","family":"Frade-Guanaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5938-0675","authenticated-orcid":false,"given":"Margareth C.","family":"Ozelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.bvth.2026.100200_bib1","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3390\/ph15080911","article-title":"Immunogenicity of current and new therapies for hemophilia A","volume":"15","author":"Prezotti","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"3","key":"10.1016\/j.bvth.2026.100200_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.bvth.2025.100082","article-title":"Inhibitor development and clinical characteristics in children with severe hemophilia A in the ATHN 8 US cohort study","volume":"2","author":"Thornburg","year":"2025","journal-title":"Blood Vessel Thromb Hemost"},{"issue":"18","key":"10.1016\/j.bvth.2026.100200_bib3","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1056\/NEJMoa1104435","article-title":"Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors","volume":"365","author":"Leissinger","year":"2011","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.bvth.2026.100200_bib4","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1111\/j.1538-7836.2007.02663.x","article-title":"Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors","volume":"5","author":"Konkle","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.bvth.2026.100200_bib5","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1182\/blood-2011-08-369132","article-title":"The principal results of the International Immune Tolerance Study: a randomized dose comparison","volume":"119","author":"Hay","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bvth.2026.100200_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0256265","article-title":"Predictors of the outcome of immune tolerance induction in patients with haemophilia A and inhibitors: the Brazilian Immune Tolerance (BrazIT) study protocol","volume":"16","author":"Camelo","year":"2021","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.bvth.2026.100200_bib7","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.bvth.2026.100200_bib8","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bvth.2026.100200_bib9","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/rth2.12475","article-title":"Emicizumab in tolerized patients with hemophilia A with inhibitors: a single-institution pediatric cohort assessing inhibitor status","volume":"5","author":"Batsuli","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"5","key":"10.1016\/j.bvth.2026.100200_bib10","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/hae.13819","article-title":"Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis","volume":"25","author":"Batsuli","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.bvth.2026.100200_bib11","doi-asserted-by":"crossref","DOI":"10.1177\/20406207211032452","article-title":"Design of an international investigator-initiated study on MOdern Treatment of Inhibitor-positiVe pATiEnts with haemophilia A (MOTIVATE)","volume":"12","author":"Escuriola Ettingshausen","year":"2021","journal-title":"Ther Adv Hematol"},{"issue":"5","key":"10.1016\/j.bvth.2026.100200_bib12","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/hae.12646","article-title":"A longitudinal evaluation of anti-FVIII antibodies demonstrated IgG4 subclass is mainly correlated with high-titre inhibitor in haemophilia A patients","volume":"21","author":"Montalv\u00e3o","year":"2015","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.bvth.2026.100200_bib13","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/hae.14100","article-title":"Inhibitor development in previously untreated patients with severe haemophilia: A comparison of included patients and outcomes between a clinical study and a registry-based study","volume":"26","author":"Jonker","year":"2020","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.bvth.2026.100200_bib14","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1365-2516.2008.01880.x","article-title":"The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy","volume":"15","author":"DiMichele","year":"2009","journal-title":"Haemophilia"},{"issue":"10","key":"10.1016\/j.bvth.2026.100200_bib15","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1182\/blood.2022016530","article-title":"Immune complications and their management in inherited and acquired bleeding disorders","volume":"140","author":"Arruda","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bvth.2026.100200_bib16","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/hae.13762","article-title":"The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab","volume":"25","author":"Carcao","year":"2019","journal-title":"Haemophilia"},{"issue":"suppl 1","key":"10.1016\/j.bvth.2026.100200_bib17","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.thromres.2012.08.262","article-title":"Circulating biomarkers","volume":"130","author":"Badimon","year":"2012","journal-title":"Thromb Res"},{"issue":"10","key":"10.1016\/j.bvth.2026.100200_bib18","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1182\/bloodadvances.2020001468","article-title":"Unexpected enhancement of FVIII immunogenicity by endothelial expression in lentivirus-transduced and transgenic mice","volume":"4","author":"Shi","year":"2020","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"10.1016\/j.bvth.2026.100200_bib19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2025-303","article-title":"AKATSUKI third interim analysis: safety of emicizumab during and after immune tolerance induction implementation","volume":"146","author":"Nogami","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.bvth.2026.100200_bib20","article-title":"Cost-effectiveness of emicizumab for the treatment of hemophilia A: a systematic review","volume":"13","author":"Chen","year":"2025","journal-title":"Front Public Health"},{"issue":"10","key":"10.1016\/j.bvth.2026.100200_bib21","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1016\/j.jtha.2025.07.010","article-title":"Predictors of immune tolerance induction success in 231 children with severe hemophilia A with high-titer inhibitors \u2013 lessons learned from the PedNet prospective cohort study","volume":"23","author":"Carcao","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.bvth.2026.100200_bib22","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/17474086.2020.1739518","article-title":"Patients with hemophilia A and inhibitors: prevention and evolving treatment paradigms","volume":"13","author":"Lillicrap","year":"2020","journal-title":"Expert Rev Hematol"}],"container-title":["Blood Vessels, Thrombosis & Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950327226000653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950327226000653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:29:00Z","timestamp":1791059340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950327226000653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2950327226000653"],"URL":"https:\/\/doi.org\/10.1016\/j.bvth.2026.100200","relation":{},"ISSN":["2950-3272"],"issn-type":[{"value":"2950-3272","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emicizumab enables rapid tolerance, reducing bleeding during low-dose ITI in pediatric hemophilia A","name":"articletitle","label":"Article Title"},{"value":"Blood Vessels, Thrombosis & Hemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bvth.2026.100200","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100200"}}